BRIEF published on 09/18/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 1 year 7 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 1 year 7 months ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 1 year 8 months ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 1 year 8 months ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 03/27/2026 at 09:30, 1 hour 31 minutes ago Amap Street Stars Launches Macao Authentic Delicacies Ranking to Drive Cultural-Tourism Innovation in the Greater Bay Area
Published on 03/27/2026 at 08:05, 2 hours 56 minutes ago Battery X Metals Announces Corporate Awareness Engagements
Published on 03/26/2026 at 23:00, 12 hours 1 minute ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 12 hours 56 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 13 hours 1 minute ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/27/2026 at 10:45, 15 minutes ago Athora Group completes acquisition of Pension Insurance Corporation Group and announces plans to relocate headquarters to the UK
Published on 03/27/2026 at 10:40, 20 minutes ago Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026
Published on 03/27/2026 at 10:23, 37 minutes ago Original-Research: HORNBACH Holding AG & Co. KGaA (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 03/27/2026 at 10:00, 1 hour ago AlphaPet Ventures welcomes Cpro Food, one of the leading super-premium brands for dog and cat food in Belgium
Published on 03/27/2026 at 09:45, 1 hour 15 minutes ago DESTINUS Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
Published on 03/26/2026 at 18:17, 16 hours 44 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 17:45, 17 hours 16 minutes ago Cegedim: profitability continues to improve
Published on 03/26/2026 at 07:30, 1 day 3 hours ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
